The White House Office of National Drug Control Policy (ONDCP) was established in 1988 by the Anti-Drug Abuse Act, making it a component of the Executive Office of the President of the United States. The ONDCP’s stated mission is to “establish policies, priorities and objectives for the nation’s drug control program” with the goals of reducing illicit drug use, manufacturing, and trafficking; drug-related crime and violence; and drug-related health consequences both domestically and globally.
The ONDCP director oversees federal, state and local policymaking’s adherence to the program’s guidelines and anti-drug strategy, and advises the president of budgeting, management, organisation and personnel changes. According to Title V of the 1988 Anti-Drug Abuse Act, the ONDCP director is obligated to oppose any efforts to legalize illicit drugs, as this would be in direct opposition to the war on drugs’ objective. Instead, the director is expected to inform the public of penalization consequences for illicit drug use, possession and distribution.
However, another problem that the Office must attempt to challenge is the rising level of prescription drug abuse among the American population and expenditure must somehow span not only the eradication of illicit drug abuse but legal drug abuse as well.
The ONDCP director is also the U.S. government’s representative on the Board of the World Anti-doping Agency to tackle drug abuse in sport.